Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2

Journal of General Virology

Volumn 92, Issue 1, 2011, Pages 188-194

  Marcos Villar, Laura ^a,b   Campagna, Michela ^b   Lopitz Otsoa, Fernando ^c   Gallego, Pedro ^b   González Santamaría, José ^b   González, Dolores ^b   Rodriguez, Manuel S ^c,d   Rivas, Carmen ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c CIC BIOGUNE   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LATENCY ASSOCIATED NUCLEAR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 2; LYSINE; PROMYELOCYTIC LEUKEMIA PROTEIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CONJUGATION; HERPES VIRUS; HUMAN HERPESVIRUS 8; MASS SPECTROMETRY; MUTANT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN MODIFICATION; SUMOYLATION;

ANTIGENS, VIRAL; B-LYMPHOCYTES; CELL LINE; HERPESVIRUS 8, HUMAN; HUMANS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMO-1 PROTEIN; SUMOYLATION; VIRUS LATENCY;

HUMAN HERPESVIRUS 8;

EID: 78651233952     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.024984-0     Document Type: Article

References (37)

1. Adamson, A. L. & Kenney, S. (2001). Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 75, 2388-2399.
2. Boggio, R. & Chiocca, S. (2006). Viruses and sumoylation: recent highlights. Curr Opin Microbiol 9, 430-436.
3. Campagna, M., Herranz, D., Garcia, M. A., Marcos-Villar, L., Gonzalez-Santamaria, J., Gallego, P., Gutierrez, S., Collado, M., Serrano, M. & other authors (2010). SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ in press. doi: 10.1038/cdd.2010.77.
4. Chakrabarti, S. R., Sood, R., Nandi, S. & Nucifora, G. (2000). Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. Proc Natl Acad Sci U S A 97, 13281-13285.
5. Chang, P. C., Izumiya, Y., Wu, C. Y., Fitzgerald, L. D., Campbell, M., Ellison, T. J., Lam, K. S., Luciw, P. A. & Kung, H. J. (2010). Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J Biol Chem 285, 5266-5273.
6. Desterro, J. M., Rodriguez, M. S. & Hay, R. T. (1998). SUMO-1 modification of IκBα inhibits NF-κB activation. Mol Cell 2, 233-239.
7. Eladad, S., Ye, T. Z., Hu, P., Leversha, M., Beresten, S., Matunis, M. J. & Ellis, N. A. (2005). Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. Hum Mol Genet 14, 1351-1365.
8. Esteban, M., Garcia, M. A., Domingo-Gil, E., Arroyo, J., Nombela, C. & Rivas, C. (2003). The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. J Gen Virol 84, 1463-1470.
9. Gill, G. (2004). SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev 18, 2046-2059.
10. Hay, R. T. (2005). SUMO: a history of modification. Mol Cell 18, 1-12.
11. Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G. & Jentsch, S. (2002). RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135-141.
12. Johnson, E. S. (2004). Protein modification by SUMO. Annu Rev Biochem 73, 355-382.
13. Joo, C. H., Shin, Y. C., Gack, M., Wu, L., Levy, D. & Jung, J. U. (2007). Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol 81, 8282-8292. (Pubitemid 47101513)
14. Kamitani, T., Kito, K., Nguyen, H. P., Wada, H., Fukuda-Kamitani, T. & Yeh, E. T. (1998). Identification of three major sentrinization sites in PML. J Biol Chem 273, 26675-26682.
15. Kerscher, O. (2007). SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep 8, 550-555.
16. Li, X., Luo, Y., Yu, L., Lin, Y., Luo, D., Zhang, H., He, Y., Kim, Y. O., Kim, Y. & other authors (2008). SENP1 mediates TNF-induced desumoylation and cytoplasmic translocation of HIPK1 to enhance ASK1-dependent apoptosis. Cell Death Differ 15, 739-750.
17. Lin, X., Sun, B., Liang, M., Liang, Y. Y., Gast, A., Hildebrand, J., Brunicardi, F. C., Melchior, F. & Feng, X. H. (2003). Opposed regulation of corepressor CtBP by SUMOylation and PDZ binding. Mol Cell 11, 1389-1396.
18. Lin, D. Y., Huang, Y. S., Jeng, J. C., Kuo, H. Y., Chang, C. C., Chao, T. T., Ho, C. C., Chen, Y. C., Lin, T. P. & other authors (2006). Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24, 341-354.
19. Lubyova, B. & Pitha, P. M. (2000). Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol 74, 8194-8201. (Pubitemid 30641667)
20. Marcos-Villar, L., Lopitz-Otsoa, F., Gallego, P., Munoz-Fontela, C., Gonzalez-Santamaria, J., Campagna, M., Shou-Jiang, G., Rodriguez, M. S. & Rivas, C. (2009). Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 83, 8849-8858.
21. Matunis, M. J., Zhang, X. D. & Ellis, N. A. (2006). SUMO: the glue that binds. Dev Cell 11, 596-597.
22. Meluh, P. B. & Koshland, D. (1995). Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Mol Biol Cell 6, 793-807.
23. Meulmeester, E. & Melchior, F. (2008). Cell biology: SUMO. Nature 452, 709-711.
24. Minty, A., Dumont, X., Kaghad, M. & Caput, D. (2000). Covalent modification of p73α by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 275, 36316-36323.
25. Rivas, C., Thlick, A. E., Parravicini, C., Moore, P. S. & Chang, Y. (2001). Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 75, 429-438.
26. Rui, H. L., Fan, E., Zhou, H. M., Xu, Z., Zhang, Y. & Lin, S. C. (2002). SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling. J Biol Chem 277, 42981-42986.
27. Seo, T., Park, J., Lim, C. & Choe, J. (2004). Inhibition of nuclear factor κB activity by viral interferon regulatory factor 3 of Kaposi's sarcoma-associated herpesvirus. Oncogene 23, 6146-6155.
28. Shin, Y. C., Joo, C. H., Gack, M. U., Lee, H. R. & Jung, J. U. (2008). Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. Cancer Res 68, 1751-1759.
29. Suzuki, T., Ichiyama, A., Saitoh, H., Kawakami, T., Omata, M., Chung, C. H., Kimura, M., Shimbara, N. & Tanaka, K. (1999). A new 30-kDa ubiquitin-related SUMO-1 hydrolase from bovine brain. J Biol Chem 274, 31131-31134. (Pubitemid 29508461)
30. Takahashi, H., Hatakeyama, S., Saitoh, H. & Nakayama, K. I. (2005). Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J Biol Chem 280, 5611-5621.
31. Tatham, M. H., Jaffray, E., Vaughan, O. A., Desterro, J. M., Botting, C. H., Naismith, J. H. & Hay, R. T. (2001). Polymeric chains of SUMO- 2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 276, 35368-35374.
32. Ulrich, H. D. (2009). The SUMO system: an overview. Methods Mol Biol 497, 3-16.
33. Vertegaal, A. C., Andersen, J. S., Ogg, S. C., Hay, R. T., Mann, M. & Lamond, A. I. (2006). Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol Cell Proteomics 5, 2298-2310. (Pubitemid 46040634)
34. Weger, S., Hammer, E. & Heilbronn, R. (2004). SUMO-1 modification regulates the protein stability of the large regulatory protein Rep78 of adeno associated virus type 2 (AAV-2). Virology 330, 284-294. (Pubitemid 39446585)
35. Wies, E., Mori, Y., Hahn, A., Kremmer, E., Sturzl, M., Fleckenstein, B. & Neipel, F. (2008). The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 111, 320-327.
36. Zhao, J. (2007). Sumoylation regulates diverse biological processes. Cell Mol Life Sci 64, 3017-3033.
37. Zhu, J., Zhu, S., Guzzo, C. M., Ellis, N. A., Sung, K. S., Choi, C. Y. & Matunis, M. J. (2008). Small ubiquitin-related modifier (SUMO) binding determines substrate recognition and paralog-selective SUMO modification. J Biol Chem 283, 29405-29415.